Evidence map›Paper›PMID 42057903›Full record

ArticleFrontiers in neuroscience2026

Retrospective longitudinal analysis of blood microRNA-7-5p as a possible progression biomarker in people with Parkinson's disease.

Shayan Abdollah Zadegan, Corrine Hutchinson, Chiamaka Onuigbo, Juan D Martinez-Lemus, Laura Talbot, E Jeffrey Metter, Marie-Francoise Doursout, Emily Tharp, Jessika Suescun, Mohammad Shahnawaz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. microRNA-7-5p and α-Synuclein SAA Predict Parkinson's Disease Phenoconversion.Annals of clinical and translational neurology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shayan Abdollah ZadeganDepartment of Neurology, The University of Tennessee Health Science Center, Memphis, TN, United States.
Corrine HutchinsonDepartment of Neurology, The University of Tennessee Health Science Center, Memphis, TN, United States.
Chiamaka OnuigboDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Juan D Martinez-LemusDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Laura TalbotDepartment of Neurology, The University of Tennessee Health Science Center, Memphis, TN, United States.
E Jeffrey MetterDepartment of Neurology, The University of Tennessee Health Science Center, Memphis, TN, United States.
Marie-Francoise DoursoutDepartment of Anesthesiology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Emily TharpDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Jessika SuescunDepartment of Neurology, Queensland University of Technology, Brisbane, QLD, Australia.
Mohammad ShahnawazDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Timothy M EllmoreDepartment of Psychology, The City College of New York, New York, NY, United States.
Mya SchiessDepartment of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States.
Christopher AdamsDepartment of Neurology, The University of Tennessee Health Science Center, Memphis, TN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: MicroRNA-7-5p (miR-7-5p) may play a neuroprotective role in people with Parkinson's disease (PwP), as it has been found to regulate Objective: The study aimed to investigate the use of miR-7-5p as a potential biomarker for disease progression in PwP by correlating it with time, clinical measures, and neurofilament light chain (NfL). Methods: We performed a longitudinal retrospective analysis of blood miR-7-5p levels in 303 Results: miR-7-5p levels decreased more rapidly in PwP compared to HCs ( Conclusion: This pattern suggests that miR-7-5p may reflect both upstream pathogenic mechanisms and downstream neuroaxonal damage. However, the loss of significance when time in the study was included in the model indicates that the changes may reflect parallel degenerative processes involving NfL and miR-7-5p. This study is novel in that it demonstrates a correlation between miR-7-5p levels, clinical severity, and NfL levels.

Indexed as

alpha-synucleinbiomarkersmicroRNAneurofilament light chainNLRP3 inflammasomeParkinson’s disease

Identifiers

PMID42057903
PMCPMC13122771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.